Zhou Jiming 4

What Happened

• Zhou Jiming, Chief Operating Officer of 20/20 Biolabs, was granted 150,000 derivative securities on April 2, 2026. The Form 4 reports the award at $0.00 per share (total reported consideration $0). This was an award/grant transaction (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-02; Form 4 filed: 2026-04-06 (timely filing).
• Amount: 150,000 derivative shares granted at $0.00 per share; total reported consideration $0.
• Shares owned after transaction: Not specified in the provided filing.
• Notable items: Classified as a derivative award (Form 4 indicates "DERIVATIVE"); filing does not specify the exact instrument type (e.g., RSUs, restricted stock, or other equity-linked award) or any tax-withholding/vesting terms.

Context

• Grants/awards are typically compensation-related and differ from open-market purchases or sales; they do not necessarily signal the insider bought shares with personal funds. For derivative grants, vesting schedules or other conditions (not detailed here) determine when the insider gains full ownership or sale ability.